Tbet+NK1.1− innate lymphoid cells (ILCs) within cancers is the missing link that can define checkpoint therapy success in cancers such as melanoma and cutaneous squamous cell carcinoma. This evidence concerns the gene TBX21 and cutaneous squamous cell carcinoma.